Treosulfan
Alkyl Sulfonates
Sold as Trecondi · TRECONDYV
- Drug class
- Alkyl Sulfonates
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 8
Overview
Treosulfan is an active pharmaceutical ingredient in the Alkyl Sulfonates group (L01AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | April 17, 2026 |
| CA Canada | Health Canada | 3 | November 26, 2025 |
| EU European Union | EMA | 1 | February 17, 2026 |
GBUnited Kingdom· MHRA
4 products
Uses
Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.
How to take
CACanada· Health Canada
3 products
Uses
TREOSULFAN FOR INJECTION (treosulfan for injection) is indicated in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) • in adult patients with AML or MDS at increased risk for standard conditioning therapies, • in pediatric patients older than 1 year old with AML or MDS Administration of treosulfan should be supervised by a physician experienced in conditioning treatment followed by alloHSCT.
Limitations of Use TREOSULFAN FOR INJECTION is not indicated for patients undergoing alloHSCT for Fanconi anemia and other DNA breakage repair disorders. 1 Pediatrics Pediatrics (> 1 year to 18 years): The use of treosulfan for injection has not been fully investigated in the pediatric population.
2 Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use of treosulfan for injection in the geriatric population is not associated with significant differences in safety or effectiveness.
EUEuropean Union· EMA
1 product
Uses
Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.
How to take
Sources & citations
- [1]MHRA (UK) · PLGB115870118 · revised April 17, 2026
- [2]Health Canada (DPD) · 02560585 · revised November 26, 2025
- [3]European Medicines Agency · EMEA/H/C/004751 · revised February 17, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.